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Abstract
Background: MicroRNAs (miRNAs) are important genetic elements that regulate the expression of thousands of
human genes. Polymorphisms affecting miRNA biogenesis, dosage and target recognition may represent
potentially functional variants. The functional consequences of single nucleotide polymorphisms (SNPs) within
critical miRNA sequences and outside of miRNA genes were previously demonstrated using both experimental and
computational methods. However, little is known about how copy number variations (CNVs) affect miRNA genes.
Results: In this study, we analyzed the co-localization of all miRNA loci with known CNV regions. Using
bioinformatic tools we identified and validated 209 copy number variable miRNA genes (CNV-miRNAs) in CNV
regions deposited in Database of Genomic Variations (DGV) and 11 CNV-miRNAs in two sets of CNVs defined as
highly polymorphic. We propose potential mechanisms of CNV-mediated variation of functional copies of miRNAs
(dosage) for different types of CNVs overlapping miRNA genes. We also showed that, consistent with their essential
biological functions, miRNA loci are underrepresented in highly polymorphic and well-validated CNV regions.
Conclusion: We postulate that CNV-miRNAs are potential functional variants and should be considered high
priority candidate variants in genotype-phenotype association studies.
Background
MicroRNAs (miRNAs) are a family of short (~20 nt),
single-stranded, noncoding RNAs that are primarily
involved in post-transcriptional down-regulation of gene
expression in most eukaryotes [1]. Specific miRNAs are
engaged in a variety of processes, including develop-
ment, cell proliferation, differentiation and apoptosis [2].
Numerous studies have demonstrated that aberrant
over-expression or down-regulation of certain miRNAs
contribute to carcinogenesis and that these miRNAs can
therefore be classified as either oncogenes (oncomirs) or
tumor suppressors, respectively [3].
Mature, functional miRNAs are generated from pri-
mary precursors (pri-miRNA) encoded either by inde-
pendent transcriptional units or within protein- or
RNA-coding genes. In mammals, maturation of miRNAs
involves two subsequent RNA cleavage steps. The first
step takes place in the nucleus and is carried out by the
Drosha nuclease to produce the secondary precursor
(pre-miRNA) [4]. The pre-miRNAs (~60 nt) possess a
hairpin structure, with the double-stranded portion
interrupted by one or more mismatched nucleotides.
Upon export to the cytoplasm, the pre-miRNA is further
processed into an miRNA duplex by the RNAse III
Dicer; [5] one of the duplex strands (passenger) is
released, and the other serves as the mature miRNA [6].
The miRNA-induced silencing complex (miRISC) inter-
acts with complementary target sequences, which are
usually located within the 3’ untranslated regions
(3’UTRs) of mRNAs, causing mRNA degradation or
inhibition of translation [7-9].
It is estimated that, in humans and other mammals,
the expression of at least one-third of protein-coding
genes is fine-tuned by approximately 1,000 miRNAs
[10,11]. Currently, over 700 human miRNAs have been
identified, and their sequences are deposited in miRBase
(the microRNA database; http://www.mirbase.org).
Polymorphisms in miRNA genes can affect the expres-
sion of many downstream-regulated genes [12,13]. The
most common form of polymorphism that affects the
function of an miRNA (e.g., the structure of miRNA
precursors, the efficiency of miRNA biogenesis and
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morphism (SNP). Computational and experimental stu-
dies have revealed many SNPs located in different parts
of pre-miRNA sequences [14-16]. The occurrence of
SNPs (including INDELs) in pre-miRNA regions is sig-
nificantly lower than that in the surrounding reference
sequences [16]. While sequences of mature miRNAs are
the most conserved, the sequences of anti-miRNAs and
the stems (outside miRNA and anti-miRNA) and loops
of pre-miRNAs are somewhat less conserved [16]. SNPs
naturally occurring within pre-miRNA sequences may
affect miRNA biogenesis and impair miRNA-mediated
gene silencing, as demonstrated by functional assays
[15,17]. Recently, large genome-wide association study
has demonstrated that also SNPs located outside (>14
kb) of pre-miRNA sequences can modulate miRNA
expression both as cis- and trans-regulators (miRNA-
eQTLs). One of identified miRNA-eQTLs (rs1522653)
was shown to correlate with expression of 5 different
miRNAs [18].
MiRNA target sites are also conserved genetic ele-
ments. Bioinformatic analyses show that SNPs are
underrepresented in both experimentally validated and
computationally predicted miRNA target sites, [16,19]
and SNPs have the potential to either disrupt or create
new miRNA target sites [19]. It has also been proposed
that target site polymorphisms may play a role in evolu-
tion by altering miRNA specificity and function.
However, little is known about copy number variation
(CNV) of miRNA genes. CNVs are segments of genomic
DNA (roughly 1 kb to 1 Mb in length) that show vari-
able numbers of copies in the genome due to deletions
or duplications. CNVs recurrently occurring in a popu-
lation are often called copy number polymorphisms
(CNPs). Only a few CNV discovery studies report the
presence of miRNAs in detected CNV regions and
recognize their potential consequences [20-22]. Indeed,
it was suggested that a comprehensive analysis of the
co-localization of miRNAs and CNVs is needed [12].
Numerous studies show that CNVs can influence the
expression of protein-coding genes in a copy number-
dependent manner [23-25]. Recent results of genome-
wide association study has confirmed such association
for dozens of protein-coding genes and showed that
CNVs capture at least 18% of the total detected genetic
variation in gene expression [26]. It seems obvious that
the expression of miRNA genes can also be modified
by CNVs. This notion is supported by results from
cancer genetics studies. For instance, there is a correla-
tion between somatic copy number variation and the
expression of miRNA genes, and miRNA genes recur-
rently amplified or lost in cancer genomes can serve as
oncogenes or cancer suppressor genes, respectively
[27-31].
In this study, by comparing the coordinates of human
miRNAs with different sets of CNV regions (DGV-
deposited and highly polymorphic), we identified over
200 human copy number variable miRNA loci.B yc o m -
paring fractions of miRNAs and the genome that are
covered by differentially validated CNV regions, we
showed that miRNA loci are underrepresented in highly
polymorphic CNVs, but not in CNVs deposited in the
DGV database. We discuss the potential functional rele-
vance of identified copy number variable miRNAs and
propose models of how different types of CNVs can
affect miRNA dosage.
Results and Discussion
Prior to bioinformatic identification of copy number
variable miRNA genes (CNV-miRNAs), we compared
the frequency of SNPs in annotated pre-miRNA
sequences (3.7 SNPs/1,000 bp) and in reference human
genome (4.8 SNPs/1,000 bp). Significantly lower number
of SNPs in the pre-miRNA sequences (Fisher’s exact
test; p < 0.0001) most likely results from SNP purifica-
tion effect and confirms general conservation of the ana-
lyzed pre-miRNA sequences. These analyses confirmed a
SNP purification effect in pre-miRNA sequences
reported previously [16]. The much higher number of
SNPs identified in annotated pre-miRNA sequences in
our study (N = 229; Additional file 1) versus N = 65
reported previously [16] results from the increased num-
ber of both SNPs (dbSNP - build 130; Apr 30, 2009;
only annotated as ‘single’; ~14 million SNPs) and miR-
NAs (miRBase - v 13.0), available in versions of data-
bases used in this study.
To identify CNV-miRNAs, we compared the positions
of miRNA loci with three sets of CNVs: ‘DGV-deposited’
(N = 29133; 30% genome coverage), ‘polymorphic-SMC’
(N = 1319; 1.2% genome coverage) [32] and ‘poly-
morphic-DC’ (N = 5037; 2.3% genome coverage) [22]
CNVs. ‘DGV-deposited’ CNVs include all 29133 CNVs
deposited in the Database of Genomic Variants (DGV
update Aug 05, 2009 - http://projects.tcag.ca/variation).
Two sets of ‘polymorphic’ CNVs (’polymorphic-SMC’
[32] and ‘polymorphic-DC’ [22]) include highly poly-
morphic CNVs (minor allele frequency >0.01) validated
by high-quality genotyping in two recent CNV-discovery
studies using CNV-dedicated high-density hybrid arrays
(combining traditional SNP probes and probes targeting
CNVs) [22,32]. In both of these studies, precise break-
points and unambiguous copy numbers were deter-
mined for each analyzed sample. All ‘DGV-deposited’
CNV-miRNA regions were further characterized by the
following validation factors: (i) number of publications
reporting CNVs (references), (ii) number of overlapping
CNVs (DGV records) and (iii) number of observations
in discovery studies (frequency) (Additional file 2). Since
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tory elements) are difficult to determine, we used the
genomic coordinates of all pre-miRNA loci deposited in
miRBase (v 13.0; N = 715) as a proxy of miRNA gene
sequences (three pre-miRNA loci located in the mito-
chondrial genome were excluded from our analysis)
[33,34]. We realize, however, that CNVs overlapping
other functional regions of miRNA coding genes (e.g.,
promoters) can also affect miRNA biogenesis and func-
tionality, and those CNVs will be missed in our analysis.
The CNV-miRNAs identified in ‘DGV-deposited’
CNVs (N = 209) and in two sets of ‘polymorphic’
CNVs (N = 4 and N = 8) are shown in Additional file
2 and Table 1, respectively. Top-validated ‘DGV-
deposited’ CNV-miRNAs are also shown in Table 2.
Most miRNA loci identified in ‘polymorphic’ CNVs
also overlapped with top-validated ‘DGV-deposited’
CNV regions (Table 1 and Table 2). All ‘polymorphic’
CNV-miRNAs were relatively frequent (combined
minor genotype frequency >0.1 in at least one HapMap
population). Among the identified miRNA-CNVs, we
found deletions (e.g., hsa-mir-384 and hsa-mir-1324),
duplications (e.g., hsa-mir-1972 and hsa-mir-1977),
and multiple duplications (multiallelic polymorphisms;
e.g., hsa-mir-1233 and hsa-mir-1268). The number of
observed copies ranged from 0 (e.g., hsa-mir-384 and
hsa-mir-650) to 6 (e.g., hsa-mir-1268).
The sequences of miRNA deposited in miRBase are
derived from discovery studies in which many strict
miRNA verification criteria were applied (e.g. hairpin
forming potential, evolutionary conservation, presence
in multiple clones/sequence reads or homogeneity of
the 5’end). The SNP frequency analysis presented in this
study also confirmed global conservation of annotated
pre-miRNA sequences. However, there is still a possibi-
lity that some of the miRNAs in the miRBase represent
experimental artifacts of false positive discoveries [35].
To provide additional data that can further validate
miRNAs identified in CNVs we have conducted bioin-
formatic analysis of their expression and conservation.
Table 1 and Table 2 show that according to different
miRNA expression resources summarized in mimiRNA
Table 1 miRNA loci localized in polymorphic CNV regions
miRNAs localized in ‘polymorphic-SMC’ CNV regions
miRNA
ID
miRNA
position
dupl. CNV region
position
genotypes CNV ID functional relevance expression (mimiRNA/[18]) conservation
mir-
1268
chr15:20014593-
20014644
chr15:19803370-
20089386
2,3,4,5,6 2057 1) recurrently deleted in
classical Hodgkin’s
lymphoma [47]
not reported/NA primates
mir-
1233
chr15:32607783-
32607864
chr15 chr15:32487975-
32617680
0,1,2,3 2082 1) not reported/NA primates
mir-
1972
chr16:15011679-
15011755
chr16 chr16:14897364-
15016088
2,3,4 2141 not reported/NA primates
mir-384 chrX:76056092-
76056179
chrX:76053855-
76057477
0,1,2 2648 in several tissues/NA mammals
miRNAs localized in ‘polymorphic-DC’ CNV regions
miRNA
ID
miRNA
position
dupl. CNV region
position
genotypes CNV ID functional relevance expression (mimiRNA/[18]) conservation
mir-
1977
chr1:556050-
556128
chrM chr1:554403-
560267
2,3,4 3.1 not reported/NA primates
mir-
1324
chr3:75762604-
75762699
chr3:75464498-
75782745
1,2 1432.2 not reported/NA primates
mir-
548i-2
chr4:9166887-
9167035
chr4:9117494-
9354801
1,2 1815.3 not reported/NA primates
mir-
1275
chr6:34075727-
34075806
chr6:34071086-
34077139
1,2 2853.1 2) upregulated in blood
cells of MS patients [41]
not reported/NA primates
mir-
1302-2
chr9:20144-
20281
chr1,
15,19
chr9:485-38531 2,3 4134_full not reported/NA primates
mir-
1233
chr15:32461562-
32461643
chr15 chr15:32450046-
32662643
2,3,4,5 6351.3 1) not reported/NA primates
mir-
1233
chr15:32607783-
32607864
chr15 chr15:32450046-
32662643
2,3,4,5 6351.3 1) not reported/NA primates
mir-650 chr22:21495270-
21495365
chr22:20711019-
21578950
0,1,2 8103_full 1) in several tissues (mostly ovary
and ovary-derived cancers)/
high
primates
dupl. - localization of duplicated copies; mimiRNA/[18] - miRNA expression according to database mimiRNA/and according to resent result of expression analysis
in primary fibroblast cells (high - high expression, absent - low or undetectable expression in fibroblast cells, NA - not analyzed).
Marcinkowska et al. BMC Genomics 2011, 12:183
http://www.biomedcentral.com/1471-2164/12/183
Page 3 of 9Table 2 miRNA loci localized in CNV regions validated by multiple overlapping CNVs
miRNAs localized in ‘DGV-deposited’ CNV regions validated by multiple overlapping CNVs
miRNA
ID
miRNA position dupl. minimal CNV
region
#
CNVs
functional relevance expression
(mimiRNA/[18])
conservation
mir-
1977
chr1:556050-
556128
chrM chr1:554340-
569354
6 not reported/NA primates
mir-149 chr2:241044091-
241044179
chr2:241039698-
241051687
6 3) downregulated in squamous cell carcinoma
of the tongue [44]
in multiple tissues/
high
vertebrates
mir-566 chr3:50185763-
50185856
chr3:50173490-
50214015
7 in several tissues/
absent
primates
mir-
1324
chr3:75762604-
75762699
chr3:75761737-
75839337
6 not reported/NA primates
mir-570 chr3:196911452-
196911548
chr3:196905807-
196918722
9 in several tissues/
absent
primates
mir-
548i-2
chr4:9166887-
9167035
chr4:9152768-
9182838
9 not reported/NA primates
mir-
548i-3
chr8:7983873-
7984021
chr8:7965981-
8024983
14 not reported/NA primates
mir-383 chr8:14755318-
14755390
chr8:14741501-
14763659
8 4) downregulated in non-obstructive
azoospermia [39]
in multiple tissues/
absent
vertebrates
mir-661 chr8:145091347-
145091435
chr8:145090343-
145104971
8 5) downregulates the expression of metastatic
tumor antigen 1 (MTA1), inhibits the motility,
invasiveness, anchorage-independent growth,
and tumorigenicity of cancer cells [48]
in several tissues
(mostly ovary and
ovary-derived
cancers)/absent
primates
mir-
1299
chr9:68292059-
68292141
chr9:68291272-
68298205
7 not reported/NA primates
mir-126 chr9:138684875-
138684959
chr9:138680837-
138688363
14 6) suppresses cell growth in colon cancer [43];
downregulates HOXA9, playing a role in the
development of many organs and often
upregulated in myeloid leukemias [37];
regulates angiogenic signaling and vascular
integrity [38]; overexpressed in ALL and AML
[42]
high, in multiple
tissues/high
vertebrates
mir-202 chr10:134911006-
134911115
chr10:134903011-
134918923
10 in several tissues/
absent
vertebrates
mir-
1268
chr15:20014593-
20014644
chr15:19975453-
20046356
37 1) see Table 1 not reported/NA primates
mir-
1233
chr15:32461562-
32461643
chr15 chr15:32461525-
32469857
9 1) see Table 1 not reported/NA primates
mir-
1233
chr15:32607783-
32607864
chr15 chr15:32599966-
32615283
17 1) see Table 1 not reported/NA primates
mir-662 chr16:760184-
760278
chr16:750040-
764098
6 in several tissues/
absent
primates
mir-
1972
chr16:68621750-
68621826
chr11 chr16:68621490-
68653097
6 not reported/NA primates
mir-142 chr17:53763592-
53763678
chr17:53751608-
53767652
11 7) increased expression correlates with rejection
of organ transplants [40]; overexpressed in pre-
B-ALL patients [46]; potentially involved in the
development of blood cancer or brain tumors
[45]
high, in multiple
tissues/absent
vertebrates
mir-
1270
chr19:20371080-
20371162
chr19:20370872-
20383238
9 not reported/NA primates
mir-663 chr20:26136822-
26136914
chr20:26136626-
26139184
6 in several tissues/NA primates
mir-650 chr22:21495270-
21495365
chr22:21494381-
21502189
38 1) see Table 1 in several tissues/
high
primates
mir-
514-2
chrX:146171153-
146171240
chrX:146168796-
146174575
6 in several tissues/NA mammals
mir-
514-3
chrX:146173851-
146173938
chrX:146168796-
146174575
6 in several tissues/NA mammals
dupl. - localization of duplicated copies; mimiRNA/[18] - miRNA expression according to database mimiRNA/and according to resent result of expression analysis
in primary fibroblast cells (high - high expression, absent - low or undetectable expression in fibroblast cells, NA - not analyzed).
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miRNAs (Table 1 and Table 2) were shown to be
expressed in at least several tissues/cell lines (detailed
expression profiles are shown in Additional file 3).
MiRNA whose expression is not reported in mimiRNA
were either not analyzed for expression or did not show
expression in the analyzed tissues. Additionally, three
out of ten (30%) top-validated CNV-miRNAs (Table 1
and Table 2) which expression in primary fibroblast cell
lines was analyzed by the micro-fluidics-based TaqMan
Human MiRNA Array show high level of expression
[18]. Based on the currently available sequence data for
miRNAs deposited in miRBase and blast searches of the
vertebrate genomic sequences we also determined evolu-
tionary conservation of the miRNAs found in top-vali-
dated CNV regions. Most of these miRNAs seem to be
specific only for primates. There are, however, 8 miR-
NAs that are conserved across mammals or vertebrates
(Table 1 and Table 2).
The functional relevance of several of the CNV-miR-
NAs identified in this survey was previously reported in
the literature (manual screening; Table 1 and Table 2).
CNV-miRNAs are involved in many processes and phe-
notypes (diseases), including organ development [37],
angiogenesis [38], male infertility [39], transplant rejec-
tion [40], multiple sclerosis [41] and cancer. Many
CNV-miRNAs are specifically deleted, amplified or
expressed in different types of cancers [42-47] and can
regulate the expression of important cancer-related
genes [37,48]. The copy number variation of those func-
tionally relevant miRNAs can modulate or predispose
one to the aforementioned phenotypes.
In the next step, we determined whether the overlap
of CNVs and miRNA loci was random (null hypothesis)
or whether the CNVs were underrepresented at these
loci (alternative hypothesis). To test this hypothesis, we
compared fractions of miRNA loci and fractions of the
genome covered by differentially defined CNV regions.
Figure 1A shows that the fraction of miRNA loci cov-
ered by two sets of ‘polymorphic’ CNVs is approxi-
mately two times lower than expected (fraction of the
covered genome). Although this effect was only margin-
ally significant (Figure 1A), it suggested that at least
highly polymorphic CNVs are under negative (purifying)
selection at miRNA genes. Conversely, the fraction of
miRNAs (0.292) covered by ‘DGV-deposited’ CNVs cor-
responded almost exactly to the fraction of the genome
covered by those CNVs (0.299). The CNV purification
effect was not observed, even after narrowing ‘DGV-
deposited’ CNV regions by different validation factors
defined above (Figure 1B and 1C). The fact that the pur-
ifying effect did not apply to the ‘DGV-deposited’ CNVs
suggested that a significant portion of these CNVs are
very rare, private, or significantly oversized or represents
false positive artifacts. This observation is consistent
with the conclusions from other recently published
results [32,49].
Although copy number variation can influence gene
expression through different mechanisms (e.g., position
effect and deletion or duplication of regulatory elements
Figure 1 Comparison of observed and expected number
(fraction) of miRNA loci located in different CNV regions.
Expected values were estimated based on the fraction of the
genome covered by CNVs. A) Graph showing the fractions of
miRNA loci (observed number of CNV-miRNAs; green bars) and the
genome (expected number of CNV-miRNAs; orange bars) covered
by two sets of ‘polymorphic’ CNVs. Binomial probabilities of equal or
lower than the observed number of miRNA loci covered by CNVs
are indicated over the bars. B) and C) The fractions of miRNA loci
and the genome covered by ‘DGV-deposited’ CNV regions gradually
narrowed by the increasing number of overlapping CNVs (DGV
records) (B) and the increasing number of reporting references (C).
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mechanism is in the variability of dosage (number of
functional copies). All of these mechanisms can affect
both protein-coding and miRNA genes. However,
mechanisms of dosage variation may be different for
protein-coding and miRNA genes. In Figure 2, potential
consequences of different CNV types overlapping differ-
ent parts of miRNA genes are proposed. Not only whole
gene amplification but also certain partial gene duplica-
tions (multiple duplications) can increase the dosage of
miRNAs. Conversely, partial gene deletions may not
always result in decreased miRNA dosage. This con-
trasts with the situation observed for protein-coding
genes, in which only duplication of the entire gene
(including the promoter and regulatory sequences) can
lead to an increased number of functional copies, and
almost every (even partial) gene deletion is deleterious.
Analysis of 11 miRNAs located in CNVs with well
defined breakpoints (Table 1) showed that (i) 3 of these
miRNAs are located in the protein coding genes which
are entirely positioned within CNVs, (ii) 4 of the miR-
NAs are located in intergenic regions and are flanked by
at least 20 kb of CNV sequences, (iii) 3 miRNAs are
located in intergenic regions flanked by short CNV
sequences (< 5 kb) and (iv) 1 miRNA is located in a
gene of which the 3’end extends beyond CNV (Addi-
tional file 4). Taking into account the average size of a
human gene (~30 kb) one can expect that miRNAs
located in large CNVs (groups (i) and (ii)) will be
expressed from genes entirely embedded within the
CNV regions. According to the model presented in Fig-
ure 2A the expression of such miRNAs very likely will
correlate with expression (number of copies) of genes
from which these miRNAs are generated (no matter
whether generated from protein-coding or non-coding
transcripts). MiRNA located in short CNVs (group (iii))
most likely will form the tandem copies transcribed
from one promoter. A number of such copies may mod-
ulate the number of miRNA precursors (pre-miRNAs)
present in one primary transcript (pri-miRNA) and thus
may modulate expression of miRNA (Figure 2D).
Expression of miRNA whose gene only partially is
embedded in CNV (iii) may be modified according to
the model shown in Figure 2B and will depend on
expression and stability of the transcript truncated at
the 3’end. Moreover, it should be noted that some pre-
miRNA sequences occur in the genome in multiple
copies. Although the functionality of such copies is still
mostly unknown, the duplicated copies of miRNA genes
may mask the effect of copy number variations that
usually affect only one copy.
Finally, not only common CNVs, but also CNVs
implicated in specific diseases can affect miRNA loci
and thus can play important role in pathogenesis. We
Figure 2 Potential mechanism of CNV-mediated variation of
miRNA dosage. Schematic representation of an miRNA gene and
its primary transcript (solid or dotted arrow-lines). The position of
the pre-miRNA sequence is indicated as a hairpin-loop structure in
the miRNA primary transcript. Dotted lines represent transcripts
unlikely to be produced due to the lack of promoter and
transcriptional start sequences. Orange boxes represent CNV regions
(deletions, duplications and dispersed duplications). The following
panels show a CNV spanning different parts of the miRNA gene: (A)
whole gene, (B) 5’-portion, (C) 3’-portion and (D) intragenic region
of the gene. +, - and 0 indicate potential increase, decrease and no
change of miRNA dosage, respectively.
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Page 6 of 9have identified 38 loci of miRNAs located in chromoso-
mal regions implicated in microdeletion/microduplica-
tion syndromes (DECYPHER v5.0 [50]) (Additional file
5). For example, six miRNA loci (hsa-mir-185, hsa-mir-
1306, hsa-mir-1286, hsa-mir-649, hsa-mir-301b and hsa-
mir-130b) are located within genomic region implicated
in DiGeorge syndrome. The role of somatic copy num-
ber variation of miRNA genes in cancer is extensively
investigated in multiple studies (e.g. [27-31]) and was
recently summarized in several review articles [51-53].
Conclusions
Although ‘polymorphic’ CNVs showed some purifying
effects at miRNA loci, there were still many miRNA loci
that overlapped with known CNV regions (Additional
file 2 and Table 2), including those that are highly vali-
dated and confirmed by high-quality genotyping (Table
1). Taking into account the CNV genome coverage
(1.2% ‘polymorphic-SMC’ and 2.3% ‘polymorphic-DC’)
and the relatively small overlapping fractions (0.39 and
0.20, respectively) between the two sets of ‘polymorphic’
CNVs analyzed in this study, we estimated that up to
10% of the human genome is covered by highly poly-
morphic CNVs. This fraction corresponds to approxi-
mately 30 highly polymorphic CNV-miRNAs in the
human genome (extrapolation of the fraction of miRNA
loci covered by highly polymorphic CNVs analyzed in
t h i ss t u d y ) .I ti sl i k e l yt h a ta tl e a s ts o m eo ft h e s eloci
are among the CNV-miRNAs identified from the top-
validated ‘DGV-deposited’ CNVs (Table 2 and Addi-
tional file 2).
CNV-miRNAs are potential functional variants and
should be considered high priority candidate variants in
genotype-phenotype association studies, especially when
they are located in regions implicated by linkage or
association studies. As indicated in Table 1, only a small
fraction of CNV-miRNAs were genotyped in three Hap-
Map populations, which provides precise information
about their polymorphisms. This is mostly due to the
lack of appropriate methods for precise characterization
of CNV polymorphisms. Although several genome-wide
approaches that substantially fulfill the above require-
ment were proposed recently, a simple and inexpensive
method that enables accurate characterization of several
CNVs of interest in a large number of samples is still
needed. The lack of such a method significantly ham-
pers the analyses of CNVs and their correlation with the
phenotype. To verify and characterize the polymorph-
isms of all CNV-miRNAs, we are developing several
medium-throughput assays suited for large scale popula-
tion studies that are focused on selected CNVs of poten-
tial functional effect. These assays will take advantage of
the MLPA-based strategy proposed previously [54-56].
Methods
Genomic coordinates (hg18) of 718 human miRNA loci,
13 600 093 SNPs (only annotated as ‘single’), 29 133
CNVs (only annotated as ‘Copy Number’)a n d5 8loci
implicated in microdeletion syndromes were down-
loaded from miRBase v13.0 http://www.mirbase.org,
dbSNP build 130; Apr 30, 2009, Database of Genomic
Variants update Aug 05, 2009 http://projects.tcag.ca/var-
iation and DECIPHER database v5.0 [50]http://decipher.
sanger.ac.uk, respectively. The coordinates of 1319
CNVs described as ‘polymorphic-SMC’ and 5037 CNVs
described as ‘polymorphic-DC’ were extracted from sup-
plementary materials of references [32] and [22], respec-
tively. The number of miRNA loci and fraction of
genome covered by CNV regions were calculated using
‘feature coverage’ and ‘base coverage’ tools available on
the Galaxy, web portal for large-scale interactive data
analyses [57].
The expression profiles of CNV-miRNAs were gener-
ated with the use of mimiRNA database [36] that sum-
marizes expression data from miRNA Atlas [58],
quantitative real-time PCR [59,60] as well as microarray
and deep sequencing data from GEO (Gene Expression
Omnibus) [61]. The assessment of evolutionary conser-
vation of microRNAs was done based on the data avail-
able at the miRBase and blast searches of the vertebrate
genomic sequences with human pre-microRNAs.
All statistical analyses were performed using Statistica
(StatSoft, Tulsa, OK). The Fisher’s exact test for com-
parison of SNPs frequency in the annotated miRNA
sequences and in the total genome sequence was calcu-
lated as described in [62], with the use of the online
tool available on webpage http://www.langsrud.com/
fisher.htm.
Additional material
Additional file 1: SNPs identified in pre-miRNA sequences. Excel
table containing list of SNPs identified in annotated pre-miRNA
sequences.
Additional file 2: miRNA identified in CNV regions. Excel table
containing list of pre-miRNA annotated sequences identified in ‘DGV-
deposited’ CNVs.
Additional file 3: Expression profiles of selected CNV-miRNAs.
Expression profiles of selected CNV-miRNAs generated with the use of
mimiRNA database [36]. The expression of all miRNAs was normalized in
each tissue to a standard score spanning 1-1,000 (1,000 represents
highest expression observed in tissue). The bars represent mean
expression measured in multiple experiments and the error bars
represent standard error of the mean. The variability of the expression
level is indicated by colors (red - lowest variability; yellow - highest
variability). Details can be found on mimiRNA webpage http://mimirna.
centenary.org.au and in [36].
Additional file 4: miRNAs located in CNVs with well defined
breakpoints. Excel table showing characteristics of miRNAs located in
CNVs with well defined breakpoints.
Marcinkowska et al. BMC Genomics 2011, 12:183
http://www.biomedcentral.com/1471-2164/12/183
Page 7 of 9Additional file 5: miRNAs located in chromosomal regions
implicated in microdeletion/microduplication syndromes. Excel table
containing list of miRNAs located in chromosomal regions implicated in
microdeletion/microduplication syndromes (DECYPHER v5.0 [50]).
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